Relevant bibliographies by topics / Biochemical Recurrence

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Biochemical Recurrence'

Author: Grafiati
Published: 4 June 2021
Last updated: 31 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Biochemical Recurrence.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Biochemical Recurrence"

1

Narita, Shintaro, Koji Mitsuzuka, Takahiro Yoneyama, Sadafumi Kawamura, Yoichi Arai, Chikara Ohyama, Tatsuo Tochigi, Takuhiro Yamaguchi, and Tomonori Habuchi. "Impact of body mass index on clinicopathologic outcome and biochemical recurrence after radical prostatectomy in 1,257 Japanese patients with prostate cancer." Journal of Clinical Oncology 31, no. 6_suppl (February 20, 2013): 176. http://dx.doi.org/10.1200/jco.2013.31.6_suppl.176.

Full text
Abstract:
176 Background: To determine the impact of body mass index (BMI) on the clinicopathological characteristics and biochemical recurrence of prostate cancer (PCa) after radical prostatectomy (RP) in Japanese men. Methods: The medical records of 1,257 men with PCa treated by radical prostatectomy without neoadjuvant therapy at four medical centers between 2001 and 2009 were retrospectively reviewed. Patients were categorized into four groups using the WHO BMI classification and recommended BMI quartiles. Associations of the various BMI categories with clinicopathological characteristics and biochemical recurrences were statistically evaluated. Biochemical recurrence was defined as a prostate specific antigen (PSA) level of >0.2 ng/ml. Results: Of the 1,257 patients, 230 (18.1%) experienced biochemical recurrence during the median follow-up period of 49 months. The median BMI was 23.8 kg/m2, and 1.4% patients were underweight, 65.4% were of normal weight, 30.9% were overweight, and 2.4% were obese (WHO classification). Preoperative PSA levels and PSA density (PSAD) were significantly higher in the underweight group than in the other groups. Pathological characteristics did not differ significantly among BMI categories. As per the WHO classification and quartile categories, biochemical recurrence rate was comparable among the BMI groups. After adjusting for other pre- and perioperative covariables, multivariate Cox proportional hazards analysis revealed that a high BMI did not have an independent impact on biochemical recurrence-free survival. Conclusions: Underweight Japanese PCa patients who underwent radical prostatectomy had higher preoperative PSA levels and PSAD. However, high BMI was not associated with increased biochemical recurrence rate.
APA, Harvard, Vancouver, ISO, and other styles
2

Moul, Judd W. "Biochemical recurrence of prostate cancer." Current Problems in Cancer 27, no. 5 (September 2003): 243–72. http://dx.doi.org/10.1016/s0147-0272(03)00032-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Amling, Christopher L. "Biochemical Recurrence after Localized Treatment." Urologic Clinics of North America 33, no. 2 (May 2006): 147–59. http://dx.doi.org/10.1016/j.ucl.2005.12.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sidaway, Peter. "Proteomic assay predicts biochemical recurrence." Nature Reviews Urology 13, no. 12 (October 25, 2016): 695. http://dx.doi.org/10.1038/nrurol.2016.215.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Michalet, Morgan, Olivier Riou, Jeremy Cottet-Moine, Florence Castan, Sophie Gourgou, Simon Valdenaire, Pierre Debuire, et al. "Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical Results of a Prospective Registry Study." Cancers 14, no. 8 (April 12, 2022): 1943. http://dx.doi.org/10.3390/cancers14081943.

Full text
Abstract:
Around 33% of patients treated by EBRT or brachytherapy will present a biochemical recurrence. SBRT is a new option for the treatment of patients with local-only recurrence. MRgRT seems to be interesting for the treatment of these recurrences. This article presents the one-year late tolerance and biochemical recurrence-free survival results of a prospective registry study. Patients with intraprostatic (or in the prostate bed) recurrence were treated with 5 to 9 fractions (median dose of 30 Gy in 5 fractions) with the MRIdian® system. PSA level and toxicities were evaluated before treatment and at three, six and 12 months after treatment. Thirty-seven patients with a median age of 74.5 years old were treated between 21 October 2019 and 7 December 2020. Acute tolerance was excellent with no grade >2 toxicities. Twelve months after treatment, we observed an increase of grade 1–2 dysuria (46% vs. 13% before treatment) and grade 1 polyuria (73% vs. 7%). The six, nine and 12-months biochemical-recurrence free survival were 97.3%, 86.5% and 65.0%. Fifteen patients (40%) presented a biochemical recurrence. Nine of these 15 patients (60%) had a persistent disease within the treated volume. In conclusion, MRgRT is safe and has promising survival results.
APA, Harvard, Vancouver, ISO, and other styles
6

Pendharkar, Arjun V., Eric S. Sussman, Allen L. Ho, Melanie G. Hayden Gephart, and Laurence Katznelson. "Cushing's disease: predicting long-term remission after surgical treatment." Neurosurgical Focus 38, no. 2 (February 2015): E13. http://dx.doi.org/10.3171/2014.10.focus14682.

Full text
Abstract:
Cushing's disease (CD) is a state of excess glucocorticoid production resulting from an adrenocorticotropic hormone (ACTH)–secreting pituitary adenoma. The gold-standard treatment for CD is transsphenoidal adenomectomy. In the hands of an experienced neurosurgeon, gross-total resection is possible in the majority of ACTH-secreting pituitary adenomas, with early postoperative remission rates ranging from 67% to 95%. In contrast to the strong data in support of resection, the clinical course of postsurgical persistent or recurrent disease remains unclear. There is significant variability in recurrence rates, with reports as high as 36% with a mean time to recurrence of 15–50 months. It is therefore important to develop biochemical criteria that define postsurgical remission and that may provide prognosis for long-term recurrence. Despite the use of a number of biochemical assessments, there is debate regarding the accuracy of these tests in predicting recurrence. Here, the authors review the various biochemical criteria and assess their utility in predicting CD recurrence after resection.
APA, Harvard, Vancouver, ISO, and other styles
7

Lages, Paulo Sergio, Luciano Prado Junior, Leonardo Prado, and Luciana Lages. "Experience of a single Brazilian center on PSMA-PET in biochemical recurrence in patients with prostate cancer." Journal of Clinical Oncology 37, no. 7_suppl (March 1, 2019): 134. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.134.

Full text
Abstract:
134 Background: Biochemical recurrence in prostate cancer is a common event, and we have data showing that PSMA-PET may guide therapy when it happens. Objectives: Verify the sensibility of PSMA-PET on biochemically recurrent prostate cancer and correlate it with PSA level and Gleason score. Methods: From October 2015 to August 2018, 547 PSMA-PET (68Ga-PSMA) was performed to evaluate prostate cancer individuals. 276 patients had already been treated from prostate cancer and were in biochemical recurrence. From these patients, 122 had information regarding Gleason Score. Results: From the 276 patients, we found 216 positive exams (78.3%). What we can see, and according to the present data we already have, is that the positivity rises with increasing PSA level. Conclusions: PSMA-PET is a useful strategy for planning treatment in patients with biochemical recurrent prostate cancer. The sensibility varies according to PSA level and Gleason Score. An interest thing observed is that the sensibility for Gleason 3+4 is similar to Gleason 3+3 and the sensibility for Gleason 4+3 is similar to 4+4, showing that the Gleason 7 disease has different behaviors, as previous shown in other trials. This dataset reinforces the importance of incorporating PSMA-PET in clinical practice.[Table: see text][Table: see text][Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
8

Luker, Gary D. "Imaging Biochemical Recurrence in Prostate Cancer." Radiology: Imaging Cancer 3, no. 4 (July 1, 2021): e219015. http://dx.doi.org/10.1148/rycan.2021219015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Simon, Nicholas I., Chris Parker, Thomas A. Hope, and Channing J. Paller. "Best Approaches and Updates for Prostate Cancer Biochemical Recurrence." American Society of Clinical Oncology Educational Book, no. 42 (April 2022): 1–8. http://dx.doi.org/10.1200/edbk_351033.

Full text
Abstract:
Biochemical recurrence develops in almost one-third of men with prostate cancer after treatment with local therapy. There are numerous options for management, including surveillance, salvage radiation, androgen deprivation therapy (ADT), and clinical trials. This article reviews the current approaches to radiation therapy, ADT, and molecular imaging in men with biochemically recurrent prostate cancer. First, radiation therapy, including selection of field, dose, and use of concurrent antiandrogen therapy, is reviewed. Next, molecular imaging is addressed, including prostate-specific membrane antigen PET imaging and its increased sensitivity in identifying sites of disease. Finally, the factors associated with starting ADT are explored, and the data supporting intermittent over continuous ADT are reviewed. Lastly, the use of prostate-specific membrane antigen PET imaging and its potential role influencing therapy are discussed.
APA, Harvard, Vancouver, ISO, and other styles
10

Trock, B., M. Han, E. B. Humphreys, A. W. Partin, M. A. Eisenberger, and P. C. Walsh. "Survival following early hormone therapy for men with rapid PSA doubling time within 2 years following radical prostatectomy." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 5065. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5065.

Full text
Abstract:
5065 Background: Early hormonal therapy has been used in the salvage setting for men with biochemical recurrence following radical prostatectomy (RP), but no studies to date have been able to evaluate whether such treatment prolongs survival. We examined the impact of salvage hormonal therapy on overall survival (OS) in a cohort with long-term follow-up, and attempted to identify the subgroup most likely to benefit. Methods: Retrospective analysis of a cohort of 488 men undergoing RP at Johns Hopkins Hospital from 1982–2004, who experienced biochemical recurrence and received no salvage therapy (n = 386) or salvage hormonal therapy (n = 102); no one received adjuvant therapy. Survival was defined from biochemical recurrence to death from all causes, and analyzed with proportional hazards models with time-dependent covariates. Results: With median follow-up of 6 years after recurrence and 9 years after RP, there were 143 deaths (29%), including 105 from prostate cancer. After adjusting for PSA doubling time (PSADT), RP Gleason score, and year of surgery, hormonal therapy did not significantly improve OS for all men, compared to no salvage therapy: hazard ratio (HR) = 0.72 (95% confidence interval (CI): 0.45–1.17), p = 0.187. However, when restricted to men with early recurrence, i.e. within 2 years of RP, and with a rapid PSADT<6 months, hormonal therapy was associated with a large, significant improvement in OS: HR = 0.25 (95% CI: 0.08–0.71), p = 0.0095. This subgroup comprised 22% of the cohort. In contrast, there was no benefit of salvage hormonal therapy in men with early recurrence and PSADT>6 months: HR = 1.96 (95% CI: 0.89–4.31), p = 0.093, nor those who recurred more than 2 years after RP, regardless of PSADT. Conclusions: This study suggests that early salvage hormonal therapy may significantly and substantially prolong overall survival in the subgroup of men who experience an early biochemical recurrence with a rapid PSADT. These results are consistent with early recurrences being indicative of metastatic disease, while later recurrences are more likely to represent local recurrence. If validated, these results may provide useful stratification criteria for clinical trials. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Biochemical Recurrence"

1

Hu, Xinhai [Verfasser]. "Risk prediction models for biochemical recurrence after radical prostatectomy / Xinhai Hu." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2017. http://d-nb.info/114842539X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Joshi, Andre. "Precision medicine in early recurrent prostate cancer: identification of metastases by PSMA PET MRI." Thesis, Queensland University of Technology, 2018. https://eprints.qut.edu.au/122472/1/Andre_Joshi_Thesis.pdf.

Full text
Abstract:
Through a prospective clinical trial exploring PSMA PET/MRI, we aimed to address the current clinical need for more sensitive and specific imaging in biochemically recurrent prostate cancer. This imaging technology has the potential to detect micro-metastatic and low volume recurrent disease, potentially altering standard of care treatment options for patients. Additionally, as a proof of principle we aimed to apply novel organoid culture technology to develop patient derived cell models to allow drug testing and next generation sequencing as part of a precision medicine approach in early recurrent prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
3

Gawlik, Anna S. "Computer Extracted Nuclear Morphologic Features from Tumor and Benign Regions of H&E and Feulgen Stained Pathology Images Predict Biochemical Recurrence and Metastasis in Prostate Cancer Patients Post-Surgery." Case Western Reserve University School of Graduate Studies / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=case1498721871812207.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhao, Zhongwei [Verfasser]. "Tissue-based microRNAs as predictors of biochemical recurrence after radical prostatectomy: What can we learn from past studies? / Zhongwei Zhao." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2019. http://d-nb.info/1202043429/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Avilés, Escobar Claudia María [Verfasser], and Jens [Akademischer Betreuer] Bedke. "Effect of multipeptide vaccination therapy on disease outcome of patients with prostate cancer and biochemical recurrence / Claudia María Avilés Escobar ; Betreuer: Jens Bedke." Tübingen : Universitätsbibliothek Tübingen, 2016. http://d-nb.info/1197694137/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Avilés, Escobar Claudia [Verfasser], and Jens [Akademischer Betreuer] Bedke. "Effect of multipeptide vaccination therapy on disease outcome of patients with prostate cancer and biochemical recurrence / Claudia María Avilés Escobar ; Betreuer: Jens Bedke." Tübingen : Universitätsbibliothek Tübingen, 2016. http://d-nb.info/1197694137/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ferreira, Adriana de Souza Sergio. "Implante permanente de sementes de iodo e prostectomia radical em portadores de câncer de próstata: análise comparativa de uma coorte de base hospitalar." Universidade Federal de Juiz de Fora (UFJF), 2010. https://repositorio.ufjf.br/jspui/handle/ufjf/2610.

Full text
Abstract:
Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-09-30T12:24:37Z No. of bitstreams: 1 adrianadesouzasergioferreira.pdf: 4960629 bytes, checksum: b90d61012929ce42f060b1462cf6d78c (MD5)
Approved for entry into archive by Diamantino Mayra (mayra.diamantino@ufjf.edu.br) on 2016-09-30T13:38:39Z (GMT) No. of bitstreams: 1 adrianadesouzasergioferreira.pdf: 4960629 bytes, checksum: b90d61012929ce42f060b1462cf6d78c (MD5)
Made available in DSpace on 2016-09-30T13:38:39Z (GMT). No. of bitstreams: 1 adrianadesouzasergioferreira.pdf: 4960629 bytes, checksum: b90d61012929ce42f060b1462cf6d78c (MD5) Previous issue date: 2010-06-24
Este estudo teve como objetivo analisar e comparar a sobrevida livre de recidiva bioquímica em cinco anos e fatores prognósticos em pacientes portadores de câncer de próstata submetidos à braquiterapia ou cirurgia radical. Foram analisados 129 pacientes com câncer de próstata, destes 64 foram submetidos à braquiterapia permanente com sementes de Iodo 125 e 75 pacientes foram tratados com prostatovesiculectomia radical, no período de janeiro de 2002 a dezembro de 2005, em um hospital da rede privada da cidade de Juiz de Fora-MG. As principais variáveis analisadas, coletadas dos prontuários dos pacientes, foram: idade, data de nascimento, PSA inicial, escore de Gleason à biópsia prostática e na peça cirúrgica para os pacientes operados, estadiamento clínico e patológico para os casos cirurgicos, volume da próstata ao pré-planejamento e no momento da braquiterapia, atividade das sementes de Iodo 125 e dosagens seriadas de PSA após o tratamento. Os pacientes foram classificados, segundo D’Amico, em grupos de risco: baixo, intermediário e alto. A recidiva bioquímica foi definida como níveis de PSA> 0,4ng/ml para os casos de prostatectomia radical e três elevações consecutivas de PSA para os pacientes implantados (ASTRO). Para estudo do efeito do tratamento na sobrevida livre de recidiva bioquímica foram geradas curvas de Kaplan-Meier, e teste de log-rank foi usado para determinar diferenças entre as curvas. A influência de múltiplas variáveis na sobrevida livre de recidiva bioquímica, como Gleason, estadiamento, iPSA, categoria de risco e idade foram estimados por regressão de Cox. No primeiro artigo, foi observada taxa de sobrevida livre de recidiva bioquímica superior (p=0,0056) para os pacientes submetidos à braquiterapia 79,70% (IC95%:66,87-87,99) quando comparado aos pacientes submetidos à cirurgia 44,30% (IC95%:23,28-63,47) sendo identificados como fatores prognósticos associados de forma independente à sobrevida livre de recidiva bioquímica a modalidade terapêutica (HR= 3,33 ;IC95% :1,41-7,88), os níveis séricos de iPSA (HR=2,54;IC95%:1,11-5,78) e a categoria de risco (HR=4,18 ;IC95%:1,89-9,23). No segundo artigo, que avaliou somente os pacientes submetidos à braquiterapia, foi verificada uma taxa de sobrevida livre de recidiva bioquimica em cinco anos, significativamente superior (p=0,0012) para os pacientes do grupo de baixo risco 91,6% (IC 95%:75,92-97,24), quando comparada com àquela dos pacientes do grupo de risco intermediário/alto 59,19% (IC 95%:36,00-76,40). A sobrevida livre de recidiva bioquimica também foi significativamente superior nos pacientes com iPSA ≤ 10ng/ml (p=0,0084) e com escore de Gleason ≤ 6 à biópsia prostática (p=0,0057). Na análise multivariada, o risco de falha bioquímica também se manteve maior nos pacientes que pertenciam ao grupo de risco moderado/alto e para pacientes com iPSA superior a 10ng/ml. Os dados de sobrevida livre de recidiva bioquimica em cinco anos, para os pacientes desta análise, tratados com braquiterapia, foram comparáveis aos da literatura.
This study aimed to analyze and compare the biochemical relapse-free survival at five years and prognostic factors in patients with prostate cancer undergoing radical surgery or brachytherapy. We analyzed 129 patients with prostate cancer, these 64 underwent brachtherapy with permanent seeds implantation and 75 patients were treated with radical prostatectomy, from January 2002 to December 2005 in a private hospital network in the city of Juiz de Fora-MG. The main variables analyzed were collected from medical records and were: age, date of birth, initial PSA, Gleason score of prostate biopsy and of surgical specimens, clinical and pathologic staging on surgical cases, the prostate volume pre-planning and at the time of brachytherapy, seed activity of lodine 125 and serial measurements of PSA after treatment. Patients were classified according to D’Amico, at risk groups; low, intermediate and high. The biochemical recurrence was defined as PSA levels>0.4 ng/ml for cases of radical prostatectomy and three consecutive elevations of PSA for patients implanted (ASTRO). For the study of the effect of the treatment on biochemical relapse-free survival Kaplan-Meier curves were generated, and log rank test was used to determine the differences among the curves. The influence of multiple variables in the biochemical relapse-free survival as age, initial PSA, Gleason score, staging and risk category was estimated by Cox regression. In the first article, was observed rate of biochemical relapse-free survival superior (p = 0.0056) for patients undergoing brachytherapy 79.70% (CI95% :66,87-87, 99) when compared with patients undergoing surgery 44.30% (CI95% :23,28-63, 47) and were identified as prognostic factors independently associated with survival free of biochemical recurrence modality therapy (HR = 3.33, CI95% :1,41-7 88), serum levels of IPSA (HR = 2.54, CI95% :1,11-5, 78) and risk category (HR = 4.18, CI95% :1,89-9, 23). In the second article, which evaluated only the patients who underwent brachytherapy, there was a rate of biochemical relapse-free survival at five years, significantly higher (p = 0.0012) for patients with low-risk group 91.6% (CI 95% :75,92-97, 24), when compared with that of patients in the intermediate/high risk group 59.19% (CI95% :36,00-76, 40).The biochemical relapse-free survival was also significantly higher in patients with IPSA ≤ 10ng/ml (p = 0.0084) and Gleason score ≤ 6 on prostate biopsy (p = 0.0057). In multivariate analysis, the risk of biochemical failure also remained higher in patients who belonged to the group of moderate / high risk and patients with IPSA more than 10ng/ml. Data from biochemical relapse-free survival at five years for the patients of this analysis were comparable to literature.
APA, Harvard, Vancouver, ISO, and other styles
8

Ilozumba, Mmadili Nancy. "Impact of Obesity and Expression of Obesity-Related Genes in the Progression of Prostate Cancer in African American Men." Thesis, University of South Florida, 2018. http://pqdtopen.proquest.com/#viewpdf?dispub=10752522.

Full text
Abstract:

ABSTRACT Background In the US, the incidence and mortality rates of prostate cancer (PCa) are higher among African American men compared to European American men. Obesity is an important risk factor of PCa. Obesity is known to alter the gene expression profiles in prostate tumors. This study evaluates the impact of obesity and the expression of obesity-related genes on the progression of PCa in African American men. Methods The primary outcome of interest is biochemical recurrence (BCR) of PCa. There were 48 African American prostate cancer patients in the study. The tissue samples included 42 normal tissues, 40 Prostate Intraepithelial Neoplasia (PIN) and 45 tumor tissues (127 tissue samples in total). We assembled 99 obesity-related genes and determined the levels of their expression in the three types of tissue samples using Nanostring Technologies. An ANOVA test was used to compare the means for gene expression among normal, PIN and tumor tissue samples. Unconditional logistic regression models were used to calculate odds ratios (ORs) and their respective 95% confidence intervals (95% CIs) to determine the association between obesity and BCR as well as gene expression and BCR. Results were regarded as statistically significant if p-values were less than 0.05. A Kaplan Meier Curve was constructed to depict the survival time and time to event (BCR) among obese and non-obese African American prostate cancer patients. Patients were followed up from the date of first surgery to the date of biochemical recurrence or date of last follow-up. Statistical analysis was done with SAS 9.4 software. Results Forty-three obesity-related genes were statistically significantly associated with biochemical recurrence. There was no association between obesity and biochemical recurrence (BCR) in obese African American men compared to non-obese African American men (OR= 2.03, 95% CI = 0.22 - 18.77, p-value= 0.53). Twenty genes showed an upward trend in gene expression among normal, PIN and tumor tissue samples including ADIPOR1, AKRIC4, ALOX12, ALOX15, CRYBB2, EIF5A, ERG, GNPDA2, HNF1B, HSD3B1, KLK4, LEP, MC4R, MTCH2, PCSK1, PIK3CB, SLC2A2, STAT1, SULT1A1, YY1. The probability of survival (not having BCR) is lower in obese African American men compared to non-obese African American men as indicted in the Kaplan Meier curve. In other words, the probability of developing BCR is higher in obese African American men compared to non-obese African American men. Conclusion We did not find a significant association between obesity and biochemical recurrence. However, we elucidated some obesity-related genes that could explain PCa carcinogenesis. Further studies are needed to determine functional significance of these selected obesity-related genes and the role they play in encouraging PCa progression in African American men.

APA, Harvard, Vancouver, ISO, and other styles
9

Ahn-Jarvis, Jennfier H. "Development of a standardized functional soy product for cancer prevention trials:Phase II evaluation of isoflavone bioavailability in men with asymptomatic prostate cancer." The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1357255127.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, Hui [Verfasser], Matthias [Akademischer Betreuer] Eiber, Wolfgang [Gutachter] Weber, and Thomas [Gutachter] Horn. "Correlation of molecular imaging of PSMA-ligand uptake with clinicohistopathological parameters and biochemical recurrence prediction in primary prostate cancer patients / Hui Wang ; Gutachter: Wolfgang Weber, Thomas Horn ; Betreuer: Matthias Eiber." München : Universitätsbibliothek der TU München, 2021. http://d-nb.info/1238374271/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Biochemical Recurrence"

1

Sinnott, Bridget, Naim M. Maalouf, Khashayar Sakhaee, and Orson W. Moe. Medical management of nephrocalcinosis and nephrolithiasis. Edited by Mark E. De Broe. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0205_update_001.

Full text
Abstract:
Conditions associated with nephrocalcinosis and nephrolithiasis are described. Some (cystinuria, urate) have specific therapies, and there are some general measure, particular for calcium-containing stones (urine volume, dietary salt, urinary citrate, thiazide diuretics). In the absence of a primary aetiology, urinary biochemical predisposing factors can be manipulated. Properly directed medical therapy is highly effective in preventing recurrence.
APA, Harvard, Vancouver, ISO, and other styles
2

Sybert, Virginia. Genetic Skin Disorders. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780195397666.001.0001.

Full text
Abstract:
This lavishly-illustrated resource represents a comprehensive survey of well over 300 distinct inherited dermatologic conditions. Each disease entry follows a consistent format, containing sections devoted to dermatologic features, associated clinical abnormalities, histopathology, biochemical and molecular information, treatment, mode of inheritance and recurrence risk, prenatal diagnosis, and information on differential diagnosis. Any clinician faced with a patient in whom the possibility for a genetic disorder of the skin exists will find this book a practical tool of immense interest.
APA, Harvard, Vancouver, ISO, and other styles
3

Dalbeth, Nicola. Gout. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0141.

Full text
Abstract:
Gout is a common and treatable disorder of purine metabolism. Gout typically presents as recurrent self-limiting episodes of severe inflammatory arthritis affecting the foot. In the presence of persistent hyperuricaemia, tophi, chronic synovitis, and joint damage may develop. Diagnosis of gout is confirmed by identification of monosodium urate (MSU) crystals using polarizing light microscopy. Hyperuricaemia is the central biochemical cause of gout. Genetic variants in certain renal tubular urate transporters including SLC2A9 and ABCG2, and dietary factors including intake of high-purine meats and seafood, beer, and fructose, contribute to development of hyperuricaemia and gout. Gout treatment includes: (1) management of the acute attack using non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or low-dose colchicine; (2) prophylaxis against gout attacks when commencing urate-lowering therapy (ULT), with NSAIDs or colchicine; and (3) long-term ULT to achieve a target serum urate of less than 0.36 mmol/litre. Interleukin (IL)-1β‎ is a central mediator of acute gouty inflammation and anti-IL-1β‎ therapies show promise for treatment of acute attacks and prophylaxis. The mainstay of ULT remains allopurinol. However, old ULT agents such as probenecid and benzbromarone and newer agents such as febuxostat and pegloticase are also effective, and should be considered in patients in whom allopurinol is ineffective or poorly tolerated. Management of gout should be considered in the context of medical conditions that frequently coexist with gout, including type 2 diabetes, hypertension, dyslipidaemia, and chronic kidney disease. Patient education is essential to ensure that acute gout attacks are promptly and safely managed, and long-term ULT is maintained.
APA, Harvard, Vancouver, ISO, and other styles
4

Dalbeth, Nicola. Gout. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0141_update_003.

Full text
Abstract:
Gout is a common and treatable disorder of purine metabolism. Gout typically presents as recurrent self-limiting episodes of severe inflammatory arthritis affecting the foot. In the presence of persistent hyperuricaemia, tophi, chronic synovitis, and joint damage may develop. Diagnosis of gout is confirmed by identification of monosodium urate (MSU) crystals using polarizing light microscopy. Hyperuricaemia is the central biochemical cause of gout. Genetic variants in certain renal tubular urate transporters including SLC2A9 and ABCG2, and dietary factors including intake of high-purine meats and seafood, beer, and fructose, contribute to development of hyperuricaemia and gout. Gout treatment includes: (1) management of the acute attack using non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or low-dose colchicine; (2) prophylaxis against gout attacks when commencing urate-lowering therapy (ULT), with NSAIDs or colchicine; and (3) long-term ULT to achieve a target serum urate of less than 0.36 mmol/litre. Interleukin (IL)-1β‎ is a central mediator of acute gouty inflammation and anti-IL-1β‎ therapies show promise for treatment of acute attacks and prophylaxis. The mainstay of ULT remains allopurinol. However, old ULT agents such as probenecid and benzbromarone and newer agents such as febuxostat and pegloticase are also effective, and should be considered in patients in whom allopurinol is ineffective or poorly tolerated. Management of gout should be considered in the context of medical conditions that frequently coexist with gout, including type 2 diabetes, hypertension, dyslipidaemia, and chronic kidney disease. Patient education is essential to ensure that acute gout attacks are promptly and safely managed, and long-term ULT is maintained.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Biochemical Recurrence"

1

Martin, Christopher, and William Lowrance. "Biochemical Recurrence After Radiation Therapy." In Prostate Cancer, 101–19. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-78646-9_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Langsenlehner, Tanja. "Biochemical Recurrence: A Valuable Endpoint?" In Radiotherapy in Prostate Cancer, 55–64. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/174_2013_904.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Williams, Stephen B., and Toni K. Choueiri. "Management of Biochemical Recurrence After Localized Treatment for Prostate Cancer." In Management of Prostate Cancer, 347–59. Totowa, NJ: Humana Press, 2012. http://dx.doi.org/10.1007/978-1-60761-259-9_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jahrreiss, Victoria, Bernhard Grubmüller, Sazan Rasul, and Shahrokh F. Shariat. "PET/CT for Detection of Biochemical Recurrence Post Radical Prostatectomy." In Robot-Assisted Radical Prostatectomy, 43–46. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-05855-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, George, Sahirzeeshan Ali, Robert Veltri, Jonathan I. Epstein, Christhunesa Christudass, and Anant Madabhushi. "Cell Orientation Entropy (COrE): Predicting Biochemical Recurrence from Prostate Cancer Tissue Microarrays." In Medical Image Computing and Computer-Assisted Intervention – MICCAI 2013, 396–403. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-40760-4_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ghose, Soumya, Rakesh Shiradkar, Mirabela Rusu, Jhimli Mitra, Rajat Thawani, Michael Feldman, Amar Gupta, Andrei Purysko, Lee Ponsky, and Anant Madabhushi. "Field Effect Induced Organ Distension (FOrge) Features Predicting Biochemical Recurrence from Pre-treatment Prostate MRI." In Lecture Notes in Computer Science, 442–49. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-66185-8_50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Meltzer, H. L. "Biochemical and Physiological Guidelines for Long-Term Rubidium Therapy." In Recurrent Mood Disorders, 214–24. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-76646-6_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Höcht, Stefan, Gunnar Lohm, Lutz Moser, and LWolfgang Hinkelbein. "Radiotherapy in Biochemical Recurrences after Surgery for Prostate Cancer." In Frontiers of Radiation Therapy and Oncology, 77–85. Basel: KARGER, 2008. http://dx.doi.org/10.1159/000139881.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pomorski, Lech, Jacek Cywiński, Krzysztof Kołomecki, Zbigniew Pasieka, Magdalena Bartos, and Krzysztof Kuzdak. "Recurrences of Thyroid Cancer After Radical Surgery and Complementary Treatment: Are Macroscopic, Microscopic, Scintigraphic, and Biochemical Criteria Sufficient in the Evaluation of Radicality of Primary Treatment?" In Molecular Staging of Cancer, 203–7. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-59349-9_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Management of biochemical recurrence following radiation therapy." In Prostate Cancer, 869–78. CRC Press, 2005. http://dx.doi.org/10.1201/b14450-93.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Biochemical Recurrence"

1

Stone, Steven, Zaina Sangale, Silvia Veneroni, Julia Reid, Maurizio Colecchia, Amy Carlson, Riccardo Valdagni, Alexander Gutin, Maria G. Daidone, and Nadia Zaffaroni. "Abstract 1186: PTEN expression predicts biochemical recurrence in prostate cancer." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mirzoyan, L., T. Maurer, R. Simon, T. Horn, M. Eiber, W. Weber, and I. Rauscher. "Pattern of failure in patients with biochemical recurrence after PSMA-radioguided surgery." In NuklearMedizin 2021 – digital. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1726763.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Grosset, Andrée-Anne, Catherine St-Pierre, Karl St-Arnaud, Kelly Aubertin, Michael Jermyn, Frédéric Leblond, and Dominique Trudel. "Abstract A014: Raman microscopy to assess biochemical recurrence risk after radical prostatectomy." In Abstracts: AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; December 2-5, 2017; Orlando, Florida. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.prca2017-a014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kumar, Addanki P., Alison Clark, Michelle R. Villarreal, Shih-Bo Huang, Suleman S. Hussain, Xiaoyu Yang, Roble G. Bedolla, et al. "Abstract PO-085: Therapeutic targeting of RPS6KB1/SQSTM1 axis to prevent biochemical recurrence." In Abstracts: AACR Virtual Special Conference on Radiation Science and Medicine; March 2-3, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1557-3265.radsci21-po-085.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Harmon, Stephanie A., William Gesztes, Denise Young, Sherif Mehralivand, Brad J. Wood, Peter A. Pinto, Gyorgy Petrovics, et al. "Abstract 2636: Combined MRI and molecular signatures of prostate cancer: Association with biochemical recurrence." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2636.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Patel, Vipul, Rahul Thaly, and Ketul Shah. "Robot-assisted radical prostatectomy: histopathologic and biochemical recurrence data at one-year follow-up." In Biomedical Optics (BiOS) 2007, edited by Nikiforos Kollias, Bernard Choi, Haishan Zeng, Reza S. Malek, Brian J. Wong, Justus F. R. Ilgner, Kenton W. Gregory, Guillermo J. Tearney, Henry Hirschberg, and Steen J. Madsen. SPIE, 2007. http://dx.doi.org/10.1117/12.701332.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ali, Sahirzeeshan, Robert Veltri, Jonathan A. Epstein, Christhunesa Christudass, and Anant Madabhushi. "Cell cluster graph for prediction of biochemical recurrence in prostate cancer patients from tissue microarrays." In SPIE Medical Imaging, edited by Metin N. Gurcan and Anant Madabhushi. SPIE, 2013. http://dx.doi.org/10.1117/12.2008695.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Berglund, Anders E., Travis Gerke, Shivanshu Awasthi, G. Daniel Grass, Hyun Y. Park, John L. Cleveland, Jong Y. Park, Kosj Yamoah, and Robert J. Rounbehler. "Abstract 5716: Tristetraprolin is a prognostic biomarker for biochemical recurrence in low Gleason score patients." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Acosta, Natalia, Jovanny Zabaleta, Rodolfo Varela, Jorge Mesa, Silvia Serrano, Jone Garay, Melody Baddoo, Cruz Nataly, Alba Lucía Combita, and María Carolina Sanabria-Salas. "Abstract B69: Aggressiveness and tumor biology in prostate cancer patients with and without biochemical recurrence." In Abstracts: Tenth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; September 25-28, 2017; Atlanta, GA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7755.disp17-b69.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hoffmann, MA, HJ Wieler, J. Müller-Hübenthal, L. Trampert, M. Miederer, and M. Schreckenberger. "Diagnostic efficacy of Gallium-68-PSMA PET/CT in 565 patients with biochemical recurrence of prostate cancer." In NuklearMedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1683573.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Biochemical Recurrence"

1

Podgorski, Izabela. Biochemical and Genetic Markers in Aggressiveness and Recurrence of Prostate Cancer: Race-Specific Links to Inflammation and Insulin Resistance. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada566642.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Biochemical Recurrence' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography